Logo image of IMGO

IMAGO BIOSCIENCES INC (IMGO) Stock Fundamental Analysis

NASDAQ:IMGO - Nasdaq - US45250K1079 - Common Stock - Currency: USD

36.01  +0.01 (+0.03%)

After market: 36.01 0 (0%)

Fundamental Rating

3

Taking everything into account, IMGO scores 3 out of 10 in our fundamental rating. IMGO was compared to 571 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMGO as it has an excellent financial health rating, but there are worries on the profitability. IMGO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IMGO has reported negative net income.
In the past year IMGO has reported a negative cash flow from operations.
IMGO Yearly Net Income VS EBIT VS OCF VS FCFIMGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 -10M -20M -30M -40M

1.2 Ratios

The profitability ratios for IMGO are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IMGO Yearly ROA, ROE, ROICIMGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 -100 -200 -300

1.3 Margins

IMGO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMGO Yearly Profit, Operating, Gross MarginsIMGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for IMGO has been increased compared to 1 year ago.
IMGO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMGO Yearly Shares OutstandingIMGO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 10M 20M 30M
IMGO Yearly Total Debt VS Total AssetsIMGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 50M 100M 150M 200M

2.2 Solvency

IMGO has an Altman-Z score of 51.58. This indicates that IMGO is financially healthy and has little risk of bankruptcy at the moment.
IMGO's Altman-Z score of 51.58 is amongst the best of the industry. IMGO outperforms 98.60% of its industry peers.
IMGO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 51.58
ROIC/WACCN/A
WACCN/A
IMGO Yearly LT Debt VS Equity VS FCFIMGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 0 50M 100M 150M 200M

2.3 Liquidity

IMGO has a Current Ratio of 13.16. This indicates that IMGO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 13.16, IMGO belongs to the best of the industry, outperforming 80.72% of the companies in the same industry.
A Quick Ratio of 13.16 indicates that IMGO has no problem at all paying its short term obligations.
IMGO has a better Quick ratio (13.16) than 80.72% of its industry peers.
Industry RankSector Rank
Current Ratio 13.16
Quick Ratio 13.16
IMGO Yearly Current Assets VS Current LiabilitesIMGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

IMGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.94%.
EPS 1Y (TTM)-69.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, IMGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.80% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y46.56%
EPS Next 2Y14.27%
EPS Next 3Y6.87%
EPS Next 5Y8.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMGO Yearly Revenue VS EstimatesIMGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026
IMGO Yearly EPS VS EstimatesIMGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IMGO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IMGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMGO Price Earnings VS Forward Price EarningsIMGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMGO Per share dataIMGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.27%
EPS Next 3Y6.87%

More info and screens

0

5. Dividend

5.1 Amount

IMGO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMAGO BIOSCIENCES INC

NASDAQ:IMGO (1/10/2023, 8:15:28 PM)

After market: 36.01 0 (0%)

36.01

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2022-11-09/amc
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners8.93%
Ins Owner Change0%
Market Cap1.22B
Analysts50.91
Price Target36.72 (1.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.58%
Min EPS beat(2)-10.45%
Max EPS beat(2)19.61%
EPS beat(4)1
Avg EPS beat(4)-3.86%
Min EPS beat(4)-13.41%
Max EPS beat(4)19.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.06
P/tB 7.06
EV/EBITDA N/A
EPS(TTM)-1.84
EYN/A
EPS(NY)-2.56
Fwd EYN/A
FCF(TTM)-1.55
FCFYN/A
OCF(TTM)-1.55
OCFYN/A
SpS0
BVpS5.1
TBVpS5.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.16
Quick Ratio 13.16
Altman-Z 51.58
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.94%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.64%
EPS Next Y46.56%
EPS Next 2Y14.27%
EPS Next 3Y6.87%
EPS Next 5Y8.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-134.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-134.7%
OCF growth 3YN/A
OCF growth 5YN/A